Sorafenib was administered concomitantly with Furosemide and Amlodipine, possibly because Sorafenib is an oral tyrosine kinase inhibitor (TKI) and inhibition of VEGF signaling interrupts angiogenesis and is associated with the development of hypertension and compensatory hypertrophy. This evidence concerns the gene VEGFA and Hypertension.